NEW YORK, NY / ACCESSWIRE / December 14, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ARGO Shareholders Click Here: https://www.zlk.com/pslra-1/argo-group-loss-submission-form?prid=34633&wire=1
OLPX Shareholders Click Here: https://www.zlk.com/pslra-1/olaplex-holdings-lawsuit-submission-form?prid=34633&wire=1
SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=34633&wire=1

* ADDITIONAL INFORMATION BELOW *

Argo Group International Holdings, Ltd. (NYSE:ARGO)

This lawsuit is on behalf of investors that purchased or otherwise acquired Argo common stock between February 13, 2018 and August 9, 2022.
Lead Plaintiff Deadline : December 20, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/argo-group-loss-submission-form?prid=34633&wire=1

According to the filed complaint, (1) Argo's reserves were wholly inadequate and its underwriting standards were not prudent as was represented; (ii) Argo had dramatically changed its underwriting policies on certain U.S. construction contracts as far back as 2018; and (iii) these policies were underwritten outside of the Company's 'core' business including in certain states and for certain exposures that were far riskier than investors understood and that the Company no longer would service moving forward.

Olaplex Holdings, Inc. (NASDAQ:OLPX)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Olaplex common stock pursuant and/or traceable to the Company's initial public offering conducted on or around September 30, 2021.
Lead Plaintiff Deadline : January 17, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/olaplex-holdings-lawsuit-submission-form?prid=34633&wire=1

According to the filed complaint, (i) macroeconomic pressures and competition in the haircare market were more robust than the Company had represented to investors; (ii) accordingly, the Company was unlikely to maintain its sales and revenue momentum; and (iii) as a result, it was unlikely that the Company would be able to achieve the financial and operational growth projected in the offering documents; and (iv) as a result, the offering documents were materially false and/or misleading and failed to state information required to be stated therein.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.
Lead Plaintiff Deadline : February 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=34633&wire=1

According to the filed complaint, defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib, but also a failure by the Company to enroll any patients in a required phase 3 confirmatory trial.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP